fda approval of tirzepatide Day 4: Zepbound (Tirzepatide – weight loss indication) Approved: November 2023 for weight management Weight Loss: Up to 22.5% in clinical trials Similar to Mounjaro, but marketed specifically for weight management FDA Grants Tirzepatide a New

remember the Krebs Cycle from high-school biology

Both require medical screening and ongoing clinician oversight to ensure safety

As more comprehensive and longer-term human studies are conducted, a clearer understanding of long-term safety, potential interactions, and cumulative effects will continue to develop

Pancreatitis: While not a contraindication, individuals with a history of pancreatitis should discuss this with their doctor, as GLP-1 receptor agonists have been associated with pancreatitis in some cases

GLP-1 (glucagon-like peptide-1) agonists mimic a hormone in the body that helps regulate blood sugar and appetite

When does Semaglutide GLP-1 peak